TNFRSF8 and neoplasm: AFM13 is a tetravalent, CD16A/CD30 bispecific Innate Cell Engager that binds CD30 on PTCL cells and CD16A on innate effector cells, thereby redirecting and enhancing the innate immune response to the tumor cells.